Humoral Immune Responses in SIV Infection of Sooty Mangabeys: Implications for HIV-1 Pathogenesis and Vaccine Design.

Natural Hosts of SIV: Implication in AIDS

Volumn , Issue , 2014, Pages 173-195

  Derdeyn, Cynthia A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B cell; Envelope glycoprotein; HIV 1; HIV 2; Neutralizing antibody; Sooty mangabey

Indexed keywords

EID: 84942683751     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-404734-1.00009-7     Document Type: Chapter

References (135)

1. Keele B.F., Jones J.H., Terio K.A., Estes J.D., Rudicell R.S., Wilson M.L., et al. Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature 2009, 460:515-519.
2. Apetrei C., Robertson D.L., Marx P.A. The history of SIVS and AIDS: epidemiology, phylogeny and biology of isolates from naturally SIV infected non-human primates (NHP) in Africa. Front Biosci 2004, 9:225-254.
3. Aghokeng A.F., Ayouba A., Mpoudi-Ngole E., Loul S., Liegeois F., Delaporte E., et al. Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions. Infect Genet Evol 2010, 10:386-396.
4. Aghokeng A.F., Liu W., Bibollet-Ruche F., Loul S., Mpoudi-Ngole E., Laurent C., et al. Widely varying SIV prevalence rates in naturally infected primate species from Cameroon. Virology 2006, 345:174-189.
5. Phillips-Conroy J.E., Jolly C.J., Petros B., Allan J.S., Desrosiers R.C. Sexual transmission of SIVagm in wild grivet monkeys. J Med Primatol 1994, 23:1-7.
6. Santiago M.L., Range F., Keele B.F., Li Y., Bailes E., Bibollet-Ruche F., et al. Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Tai Forest, Cote d'Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2. J Virol 2005, 79:12515-12527.
7. Ma D., Jasinska A., Kristoff J., Grobler J.P., Turner T., Jung Y., et al. SIVagm infection in wild African green monkeys from South Africa: epidemiology, natural history, and evolutionary considerations. PLoS Pathog 2013, 9:e1003011.
8. Gao F., Bailes E., Robertson D.L., Chen Y., Rodenburg C.M., Michael S.F., et al. Origin of HIV-1 in the chimpanzee pan troglodytes troglodytes. Nature 1999, 397:436-441.
9. Keele B.F., Van Heuverswyn F., Li Y., Bailes E., Takehisa J., Santiago M.L., et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006, 313:523-526.
10. Clavel F., Guyader M., Guetard D., Salle M., Montagnier L., Alizon M. Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature 1986, 324:691-695.
11. Clavel F., Mansinho K., Chamaret S., Guetard D., Favier V., Nina J., et al. Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med 1987, 316:1180-1185.
12. Guyader M., Emerman M., Sonigo P., Clavel F., Montagnier L., Alizon M. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature 1987, 326:662-669.
13. Chakrabarti L., Guyader M., Alizon M., Daniel M.D., Desrosiers R.C., Tiollais P., et al. Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses. Nature 1987, 328:543-547.
14. Apetrei C., Kaur A., Lerche N.W., Metzger M., Pandrea I., Hardcastle J., et al. Molecular epidemiology of simian immunodeficiency virus SIVsm in U.S. primate centers unravels the origin of SIVmac and SIVstm. J Virol 2005, 79:8991-9005.
15. Apetrei C., Lerche N.W., Pandrea I., Gormus B., Silvestri G., Kaur A., et al. Kuru experiments triggered the emergence of pathogenic SIVmac. AIDS 2006, 20:317-321.
16. Daniel M.D., Letvin N.L., King N.W., Kannagi M., Sehgal P.K., Hunt R.D., et al. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 1985, 228:1201-1204.
17. Mansfield K.G., Lerch N.W., Gardner M.B., Lackner A.A. Origins of simian immunodeficiency virus infection in macaques at the New England Regional Primate Research Center. J Med Primatol 1995, 24:116-122.
18. Murphey-Corb M., Martin L.N., Rangan S.R., Baskin G.B., Gormus B.J., Wolf R.H., et al. Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys. Nature 1986, 321:435-437.
19. Fultz P.N., McClure H.M., Anderson D.C., Swenson R.B., Anand R., Srinivasan A. Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys). Proc Natl Acad Sci USA 1986, 83:5286-5290.
20. Hirsch V.M., Olmsted R.A., Murphey-Corb M., Purcell R.H., Johnson P.R. An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 1989, 339:389-392.
21. Hamel D.J., Sankale J.L., Eisen G., Meloni S.T., Mullins C., Gueye-Ndiaye A., et al. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res Hum Retroviruses 2007, 23:1189-1196.
22. Nyamweya S., Hegedus A., Jaye A., Rowland-Jones S., Flanagan K.L., Macallan D.C. Comparing HIV-1 and HIV-2 infection: lessons for viral immunopathogenesis. Rev Med Virol 2013, 23:221-240.
23. van der Loeff M.F., Awasana A.A., Sarge-Njie R., van der Sande M., Jaye A., Sabally S., et al. Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. Int J Epidemiol 2006, 35:1322-1328.
24. Fideli U.S., Allen S.A., Musonda R., Trask S., Hahn B.H., Weiss H., et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in africa. AIDS Res Hum Retroviruses 2001, 17:901-910.
25. Raugi D.N., Gottlieb G.S., Sow P.S., Toure M., Sall F., Gaye A., et al. HIV-1 outcompetes HIV-2 in dually infected senegalese subjects with low CD4 counts. AIDS 2013, 27(15):2441-2450.
26. Rowland-Jones S.L., Whittle H.C. Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1?. Nat Immunol 2007, 8:329-331.
27. Johnson P.R., Hirsch V.M. SIV infection of macaques as a model for AIDS pathogenesis. Int Rev Immunol 1992, 8:55-63.
28. Kestler H.W., Naidu Y.N., Kodama T., King N.W., Daniel M.D., Li Y., et al. Use of infectious molecular clones of simian immunodeficiency virus for pathogenesis studies. J Med Primatol 1989, 18:305-309.
29. Naidu Y.M., Kestler H.W., Li Y., Butler C.V., Silva D.P., Schmidt D.K., et al. Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac. J Virol 1988, 62:4691-4696.
30. Klatt N.R., Silvestri G., Hirsch V. Nonpathogenic simian immunodeficiency virus infections. Cold Spring Harb Perspect Med 2012, 2:a007153.
31. Moir S., Fauci A.S. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol 2008, 122:12-19. quiz 20-11.
32. Pantaleo G., Cohen O., Graziosi C., Vaccarezza M., Paolucci S., Demarest J.F., et al. Immunopathogenesis of HIV infection. AIDS: biology, diagnosis, treatment and prevention 1997, Lippincott-Raven Publishers, Philadelphia (PA). 4th ed. J. Vincent, T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
33. Schmitt N., Ueno H. Human T follicular helper cells: development and subsets. Adv Exp Med Biol 2013, 785:87-94.
34. Martinot A.J., Meythaler M., Pozzi L.A., Dalecki Boisvert K., Knight H., Walsh D., et al. Acute SIV infection in sooty mangabey monkeys is characterized by rapid virus clearance from lymph nodes and absence of productive infection in germinal centers. PLoS One 2013, 8:e57785.
35. Brenchley J.M., Vinton C., Tabb B., Hao X.P., Connick E., Paiardini M., et al. Differential infection patterns of CD4+ T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections. Blood 2012, 120:4172-4181.
36. Xu Y., Weatherall C., Bailey M., Alcantara S., De Rose R., Estaquier J., et al. Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques. J Virol 2013, 87:3760-3773.
37. Schmitz J.E., Zahn R.C., Brown C.R., Rett M.D., Li M., Tang H., et al. Inhibition of adaptive immune responses leads to a fatal clinical outcome in SIV-infected pigtailed macaques but not vervet African green monkeys. PLoS Pathog 2009, 5:e1000691.
38. Zahn R.C., Rett M.D., Li M., Tang H., Korioth-Schmitz B., Balachandran H., et al. Suppression of adaptive immune responses during primary SIV infection of sabaeus African green monkeys delays partial containment of viremia but does not induce disease. Blood 2010, 115:3070-3078.
39. Kaur A., Di Mascio M., Barabasz A., Rosenzweig M., McClure H.M., Perelson A.S., et al. Dynamics of T- and B-lymphocyte turnover in a natural host of simian immunodeficiency virus. J Virol 2008, 82:1084-1093.
40. Li B., Stefano-Cole K., Kuhrt D.M., Gordon S.N., Else J.G., Mulenga J., et al. Nonpathogenic simian immunodeficiency virus infection of sooty mangabeys is not associated with high levels of autologous neutralizing antibodies. J Virol 2010, 84:6248-6253.
41. De Boer R.J., Mohri H., Ho D.D., Perelson A.S. Turnover rates of B cells, T cells, and NK cells in simian immunodeficiency virus-infected and uninfected rhesus macaques. J Immunol 2003, 170:2479-2487.
42. Fultz P.N., Stricker R.B., McClure H.M., Anderson D.C., Switzer W.M., Horaist C. Humoral response to SIV/SMM infection in macaque and mangabey monkeys. J Acquir Immune Defic Syndr 1990, 3:319-329.
43. Kaur A., Grant R.M., Means R.E., McClure H., Feinberg M., Johnson R.P. Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques. J Virol 1998, 72:9597-9611.
44. Boliar S., Murphy M.K., Tran T.C., Carnathan D.G., Armstrong W.S., Silvestri G., et al. B-Lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth. J Virol 2012, 86:8031-8040.
45. Scinicariello F., Masseoud F., Jayashankar L., Attanasio R. Sooty mangabey (Cercocebus torquatus atys) IGHG and IGHA genes. Immunogenetics 2006, 58:955-965.
46. Ahmed R., Burton D.R. Viral vaccines: past successes and future challenges. Curr Opin Virol 2013, 3(3):307-308.
47. Burton D.R., Ahmed R., Barouch D.H., Butera S.T., Crotty S., Godzik A., et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012, 12:396-407.
48. Nabel G.J., Kwong P.D., Mascola J.R. Progress in the rational design of an AIDS vaccine. Philos Trans R Soc Lond B Biol Sci 2011, 366:2759-2765.
49. Wertheim J.O., Worobey M. Dating the age of the SIV lineages that gave rise to HIV-1 and HIV-2. PLoS Comput Biol 2009, 5:e1000377.
50. Decker J.M., Bibollet-Ruche F., Wei X.P., Wang S., Levy D.N., Wang W., et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005, 201:1-14.
51. Bottiger B., Karlsson A., Andreasson P.A., Naucler A., Costa C.M., Norrby E., et al. Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site. J Virol 1990, 64:3492-3499.
52. Kong R., Li H., Bibollet-Ruche F., Decker J.M., Zheng N.N., Gottlieb G.S., et al. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J Virol 2012, 86:947-960.
53. Kong R., Li H., Georgiev I., Changela A., Bibollet-Ruche F., Decker J.M., et al. Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. J Virol 2012, 86:12115-12128.
54. Lopker M., Easlick J., Sterrett S., Decker J.M., Barbian H., Learn G., et al. Heterogeneity in neutralization sensitivity of viruses comprising the SIVsmE660 isolate and vaccine challenge stock. J Virol 2013, 87(10):5477-5492.
55. Bar K.J., Tsao C.Y., Iyer S.S., Decker J.M., Yang Y., Bonsignori M., et al. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog 2012, 8:e1002721.
56. Gray E.S., Moody M.A., Wibmer C.K., Chen X., Marshall D., Amos J., et al. Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. J Virol 2011, 85:7719-7729.
57. Kwong P.D., Mascola J.R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012, 37:412-425.
58. Lynch R.M., Rong R., Boliar S., Sethi A., Li B., Mulenga J., et al. The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J Virol 2011, 85:905-915.
59. Murphy M.K., Yue L., Pan R., Boliar S., Sethi A., Tian J., et al. Viral escape from neutralizing antibodies in early subtype a HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog 2013, 9:e1003173.
60. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445:732-737.
61. Bou-Habib D.C., Roderiquez G., Oravecz T., Berman P.W., Lusso P., Norcross M.A. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994, 68:6006-6013.
62. Davis K.L., Bibollet-Ruche F., Li H., Decker J.M., Kutsch O., Morris L., et al. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol 2009, 83:1240-1259.
63. Moore P.L., Gray E.S., Choge I.A., Ranchobe N., Mlisana K., Karim S.S., et al. The c3-v4 region is a major target of autologous neutralizing antibodies in Hiv-1 subtype C infection. J Virol 2008, 82(4):1860-1869.
64. Kuwata T., Takaki K., Yoshimura K., Enomoto I., Wu F., Ourmanov I., et al. Conformational epitope consisting of the v3 and v4 loops as a target for potent and broad neutralization of simian immunodeficiency viruses. J Virol 2013, 87:5424-5436.
65. Yeh W.W., Brassard L.M., Miller C.A., Basavapathruni A., Zhang J., Rao S.S., et al. Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys. J Virol 2012, 86:7052-7059.
66. Gray E.S., Taylor N., Wycuff D., Moore P.L., Tomaras G.D., Wibmer C.K., et al. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol 2009, 83:8925-8937.
67. Lynch R.M., Tran L., Louder M.K., Schmidt S.D., Cohen M., Dersimonian R., et al. The development of CD4 binding site antibodies during HIV-1 infection. J Virol 2012, 86:7588-7595.
68. Moore P.L., Gray E.S., Choge I.A., Ranchobe N., Mlisana K., Abdool Karim S.S., et al. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol 2008, 82:1860-1869.
69. Tang H., Robinson J.E., Gnanakaran S., Li M., Rosenberg E.S., Perez L.G., et al. Epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals. J Virol 2011, 85:9286-9299.
70. de Silva T.I., Aasa-Chapman M., Cotten M., Hue S., Robinson J., Bibollet-Ruche F., et al. Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J Virol 2012, 86:930-946.
71. Ozkaya Sahin G., Holmgren B., da Silva Z., Nielsen J., Nowroozalizadeh S., Esbjornsson J., et al. Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1. J Virol 2012, 86:961-971.
72. Stansell E., Desrosiers R.C. Fundamental difference in the content of high-mannose carbohydrate in the HIV-1 and HIV-2 lineages. J Virol 2010, 84:8998-9009.
73. Seaman M.S., Janes H., Hawkins N., Grandpre L.E., Devoy C., Giri A., et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 2010, 84:1439-1452.
74. Wu F., Ourmanov I., Kuwata T., Goeken R., Brown C.R., Buckler-White A., et al. Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques. J Virol 2012, 86:8835-8847.
75. Gray E.S., Moore P.L., Choge I.A., Decker J.M., Bibollet-Ruche F., Li H., et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 2007, 81:6187-6196.
76. Li B., Decker J.M., Johnson R.W., Bibollet-Ruche F., Wei X., Mulenga J., et al. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 2006, 80:5211-5218.
77. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
78. Moore P.L., Gray E.S., Wibmer C.K., Bhiman J.N., Nonyane M., Sheward D.J., et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 2012, 18:1688-1692.
79. Moore P.L., Ranchobe N., Lambson B.E., Gray E.S., Cave E., Abrahams M.R., et al. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 2009, 5:e1000598.
80. Rong R., Li B., Lynch R.M., Haaland R.E., Murphy M.K., Mulenga J., et al. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog 2009, 5:e1000594.
81. Lauren A., Thorstensson R., Fenyo E.M. Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): the kinetics of evolution to neutralization resistance are related to progression rate of disease. J Gen Virol 2006, 87:595-606.
82. Clapham P.R., Weber J.N., Whitby D., McIntosh K., Dalgleish A.G., Maddon P.J., et al. Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature 1989, 337:368-370.
83. Dalgleish A.G., Beverley P.C., Clapham P.R., Crawford D.H., Greaves M.F., Weiss R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312:763-767.
84. Klatzmann D., Champagne E., Chamaret S., Gruest J., Guetard D., Hercend T., et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984, 312:767-768.
85. Sattentau Q.J., Clapham P.R., Weiss R.A., Beverley P.C., Montagnier L., Alhalabi M.F., et al. The human and simian immunodeficiency viruses HIV-1, HIV-2 and SIV interact with similar epitopes on their cellular receptor, the CD4 molecule. AIDS 1988, 2:101-105.
86. Francella N., Gwyn S.E., Yi Y., Li B., Xiao P., Elliott S.T., et al. CD4+ T cells support production of SIV Env antibodies that enforce CD4-dependent entry and shape tropism in vivo. J Virol 2013, 87(17):9719-9732.
87. Thomas E.R., Shotton C., Weiss R.A., Clapham P.R., McKnight A. CD4-dependent and CD4-independent HIV-2: consequences for neutralization. AIDS 2003, 17:291-300.
88. Edinger A.L., Mankowski J.L., Doranz B.J., Margulies B.J., Lee B., Rucker J., et al. CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. Proc Natl Acad Sci USA 1997, 94:14742-14747.
89. Martin K.A., Wyatt R., Farzan M., Choe H., Marcon L., Desjardins E., et al. CD4-independent binding of SIV gp120 to rhesus CCR5. Science 1997, 278:1470-1473.
90. Mori K., Rosenzweig M., Desrosiers R.C. Mechanisms for adaptation of simian immunodeficiency virus to replication in alveolar macrophages. J Virol 2000, 74:10852-10859.
91. Pohlmann S., Davis C., Meister S., Leslie G.J., Otto C., Reeves J.D., et al. Amino acid 324 in the simian immunodeficiency virus SIVmac V3 loop can confer CD4 independence and modulate the interaction with CCR5 and alternative coreceptors. J Virol 2004, 78:3223-3232.
92. Puffer B.A., Altamura L.A., Pierson T.C., Doms R.W. Determinants within gp120 and gp41 contribute to CD4 independence of SIV Envs. Virology 2004, 327:16-25.
93. Puffer B.A., Pohlmann S., Edinger A.L., Carlin D., Sanchez M.D., Reitter J., et al. CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol 2002, 76:2595-2605.
94. Reeves J.D., Hibbitts S., Simmons G., McKnight A., Azevedo-Pereira J.M., Moniz-Pereira J., et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J Virol 1999, 73:7795-7804.
95. Schenten D., Marcon L., Karlsson G.B., Parolin C., Kodama T., Gerard N., et al. Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells. J Virol 1999, 73:5373-5380.
96. Ortiz A.M., Klatt N.R., Li B., Yi Y., Tabb B., Hao X.P., et al. Depletion of CD4(+) T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques. J Clin Invest 2011, 121:4433-4445.
97. Apetrei C., Gautam R., Sumpter B., Carter A.C., Gaufin T., Staprans S.I., et al. Virus subtype-specific features of natural simian immunodeficiency virus SIVsmm infection in sooty mangabeys. J Virol 2007, 81:7913-7923.
98. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.
99. Bazan H.A., Alkhatib G., Broder C.C., Berger E.A. Patterns of CCR5, CXCR4, and CCR3 usage by envelope glycoproteins from human immunodeficiency virus type 1 primary isolates. J Virol 1998, 72:4485-4491.
100. Berger E.A., Murphy P.M., Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999, 17:657-700.
101. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P.D., et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85:1135-1148.
102. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
103. Doranz B.J., Rucker J., Yi Y., Smyth R.J., Samson M., Peiper S.C., et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996, 85:1149-1158.
104. Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
105. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven- transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
106. Moore J.P., Kitchen S.G., Pugach P., Zack J.A. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004, 20:111-126.
107. Tscherning C., Alaeus A., Fredriksson R., Bjorndal A., Deng H., Littman D.R., et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 1998, 241:181-188.
108. Zhang L., He T., Huang Y., Chen Z., Guo Y., Wu S., et al. Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J Virol 1998, 72:9307-9312.
109. Peden K.W., Farber J.M. Coreceptors for human immunodeficiency virus and simian immunodeficiency virus. Adv Pharmacol 2000, 48:409-478.
110. Blaak H., Boers P.H., Gruters R.A., Schuitemaker H., van der Ende M.E., Osterhaus A.D. CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia. J Virol 2005, 79:1686-1700.
111. Bron R., Klasse P.J., Wilkinson D., Clapham P.R., Pelchen-Matthews A., Power C., et al. Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein. J Virol 1997, 71:8405-8415.
112. Deng H.K., Unutmaz D., KewalRamani V.N., Littman D.R. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 1997, 388:296-300.
113. Edinger A.L., Hoffman T.L., Sharron M., Lee B., O'Dowd B., Doms R.W. Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins. Virology 1998, 249:367-378.
114. Farzan M., Choe H., Martin K., Marcon L., Hofmann W., Karlsson G., et al. Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J Exp Med 1997, 186:405-411.
115. Guillon C., van der Ende M.E., Boers P.H., Gruters R.A., Schutten M., Osterhaus A.D. Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities. J Virol 1998, 72:6260-6263.
116. Marcon L., Choe H., Martin K.A., Farzan M., Ponath P.D., Wu L., et al. Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239. J Virol 1997, 71:2522-2527.
117. McKnight A., Dittmar M.T., Moniz-Periera J., Ariyoshi K., Reeves J.D., Hibbitts S., et al. A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4. J Virol 1998, 72:4065-4071.
118. Morner A., Bjorndal A., Albert J., Kewalramani V.N., Littman D.R., Inoue R., et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999, 73:2343-2349.
119. Owen S.M., Ellenberger D., Rayfield M., Wiktor S., Michel P., Grieco M.H., et al. Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. J Virol 1998, 72:5425-5432.
120. Zhang Y., Lou B., Lal R.B., Gettie A., Marx P.A., Moore J.P. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J Virol 2000, 74:6893-6910.
121. Elliott S.T., Riddick N.E., Francella N., Paiardini M., Vanderford T.H., Li B., et al. Cloning and analysis of sooty mangabey alternative coreceptors that support simian immunodeficiency virus SIVsmm entry independently of CCR5. J Virol 2012, 86:898-908.
122. Chen Z., Gettie A., Ho D.D., Marx P.A. Primary SIVsm isolates use the CCR5 coreceptor from sooty mangabeys naturally infected in west Africa: a comparison of coreceptor usage of primary SIVsm, HIV-2, and SIVmac. Virology 1998, 246:113-124.
123. Milush J.M., Reeves J.D., Gordon S.N., Zhou D., Muthukumar A., Kosub D.A., et al. Virally induced CD4+ T cell depletion is not sufficient to induce AIDS in a natural host. J Immunol 2007, 179:3047-3056.
124. Riddick N.E., Hermann E.A., Loftin L.M., Elliott S.T., Wey W.C., Cervasi B., et al. A novel CCR5 mutation common in sooty mangabeys reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in vivo. PLoS Pathog 2010, 6:e1001064.
125. Finzi A., Pacheco B., Xiang S.H., Pancera M., Herschhorn A., Wang L., et al. Lineage-specific differences between human and simian immunodeficiency virus regulation of gp120 trimer association and CD4 binding. J Virol 2012, 86:8974-8986.
126. Xiang S.H., Kwong P.D., Gupta R., Rizzuto C.D., Casper D.J., Wyatt R., et al. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 2002, 76:9888-9899.
127. Demma L.J., Logsdon J.M., Vanderford T.H., Feinberg M.B., Staprans S.I. SIVsm quasispecies adaptation to a new simian host. PLoS Pathog 2005, 1:e3.
128. Vanderford T.H., Demma L.J., Feinberg M.B., Staprans S.I., Logsdon J.M. Adaptation of a diverse simian immunodeficiency virus population to a new host is revealed through a systematic approach to identify amino acid sites under selection. Mol Biol Evol 2007, 24:660-669.
129. Fischer W., Apetrei C., Santiago M.L., Li Y., Gautam R., Pandrea I., et al. Distinct evolutionary pressures underlie diversity in simian immunodeficiency virus and human immunodeficiency virus lineages. J Virol 2012, 86:13217-13231.
130. Shpaer E.G., Mullins J.I. Rates of amino acid change in the envelope protein correlate with pathogenicity of primate lentiviruses. J Mol Evol 1993, 37:57-65.
131. Barroso H., Taveira N. Evidence for negative selective pressure in HIV-2 evolution in vivo. Infect Genet Evol 2005, 5:239-246.
132. Skar H., Borrego P., Wallstrom T.C., Mild M., Marcelino J.M., Barroso H., et al. HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients. J Virol 2010, 84:7412-7415.
133. Zhang M., Gaschen B., Blay W., Foley B., Haigwood N., Kuiken C., et al. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 2004, 14:1229-1246.
134. Demma L.J., Vanderford T.H., Logsdon J.M., Feinberg M.B., Staprans S.I. Evolution of the uniquely adaptable lentiviral envelope in a natural reservoir host. Retrovirology 2006, 3:19.
135. Chahroudi A., Meeker T., Lawson B., Ratcliffe S., Else J., Silvestri G. Mother-to-infant transmission of simian immunodeficiency virus is rare in sooty mangabeys and is associated with low viremia. J Virol 2011, 85:5757-5763.